<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1d3 20150301//EN" "http://jats.nlm.nih.gov/publishing/1.1d3/JATS-journalpublishing1.dtd">
<article article-type="research-article" dtd-version="1.1d3" xml:lang="en" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">PLoS ONE</journal-id>
<journal-id journal-id-type="publisher-id">plos</journal-id>
<journal-id journal-id-type="pmc">plosone</journal-id>
<journal-title-group>
<journal-title>PLOS ONE</journal-title>
</journal-title-group>
<issn pub-type="epub">1932-6203</issn>
<publisher>
<publisher-name>Public Library of Science</publisher-name>
<publisher-loc>San Francisco, CA USA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1371/journal.pone.0185053</article-id>
<article-id pub-id-type="publisher-id">PONE-D-17-13860</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Research Article</subject>
</subj-group>
<subj-group subj-group-type="Discipline-v3"><subject>Research and analysis methods</subject><subj-group><subject>Mathematical and statistical techniques</subject><subj-group><subject>Statistical methods</subject><subj-group><subject>Meta-analysis</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Physical sciences</subject><subj-group><subject>Mathematics</subject><subj-group><subject>Statistics (mathematics)</subject><subj-group><subject>Statistical methods</subject><subj-group><subject>Meta-analysis</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Genetics</subject><subj-group><subject>Gene expression</subject><subj-group><subject>RNA processing</subject><subj-group><subject>RNA splicing</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Biochemistry</subject><subj-group><subject>Nucleic acids</subject><subj-group><subject>RNA</subject><subj-group><subject>RNA processing</subject><subj-group><subject>RNA splicing</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Genetics</subject><subj-group><subject>Mutation</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Oncology</subject><subj-group><subject>Cancers and neoplasms</subject><subj-group><subject>Hematologic cancers and related disorders</subject><subj-group><subject>Leukemias</subject><subj-group><subject>Myeloid leukemia</subject><subj-group><subject>Acute myeloid leukemia</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Hematology</subject><subj-group><subject>Hematologic cancers and related disorders</subject><subj-group><subject>Leukemias</subject><subj-group><subject>Myeloid leukemia</subject><subj-group><subject>Acute myeloid leukemia</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Research and analysis methods</subject><subj-group><subject>Database and informatics methods</subject><subj-group><subject>Biological databases</subject><subj-group><subject>Mutation databases</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Genetics</subject><subj-group><subject>Mutation</subject><subj-group><subject>Mutation databases</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Diagnostic medicine</subject><subj-group><subject>Prognosis</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Science policy</subject><subj-group><subject>Research integrity</subject><subj-group><subject>Publication ethics</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Oncology</subject><subj-group><subject>Cancers and neoplasms</subject><subj-group><subject>Hematologic cancers and related disorders</subject><subj-group><subject>Myelodysplastic syndromes</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Hematology</subject><subj-group><subject>Hematologic cancers and related disorders</subject><subj-group><subject>Myelodysplastic syndromes</subject></subj-group></subj-group></subj-group></subj-group></article-categories>
<title-group>
<article-title>Prognostic value of <italic>SRSF2</italic> mutations in patients with de novo myelodysplastic syndromes: A meta-analysis</article-title>
<alt-title alt-title-type="running-head">Prognostic value of <italic>SRSF2</italic> mutations in MDS</alt-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Zheng</surname>
<given-names>Xue</given-names>
</name>
<role content-type="http://credit.casrai.org/">Conceptualization</role>
<role content-type="http://credit.casrai.org/">Data curation</role>
<role content-type="http://credit.casrai.org/">Formal analysis</role>
<role content-type="http://credit.casrai.org/">Investigation</role>
<role content-type="http://credit.casrai.org/">Methodology</role>
<role content-type="http://credit.casrai.org/">Project administration</role>
<role content-type="http://credit.casrai.org/">Validation</role>
<role content-type="http://credit.casrai.org/">Visualization</role>
<role content-type="http://credit.casrai.org/">Writing – original draft</role>
<role content-type="http://credit.casrai.org/">Writing – review &amp; editing</role>
<xref ref-type="aff" rid="aff001"><sup>1</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Zhan</surname>
<given-names>Zhi</given-names>
</name>
<role content-type="http://credit.casrai.org/">Data curation</role>
<role content-type="http://credit.casrai.org/">Investigation</role>
<xref ref-type="aff" rid="aff002"><sup>2</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Naren</surname>
<given-names>Duolan</given-names>
</name>
<role content-type="http://credit.casrai.org/">Data curation</role>
<role content-type="http://credit.casrai.org/">Investigation</role>
<xref ref-type="aff" rid="aff001"><sup>1</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Li</surname>
<given-names>Jing</given-names>
</name>
<role content-type="http://credit.casrai.org/">Formal analysis</role>
<role content-type="http://credit.casrai.org/">Methodology</role>
<xref ref-type="aff" rid="aff003"><sup>3</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Yan</surname>
<given-names>Tianyou</given-names>
</name>
<role content-type="http://credit.casrai.org/">Formal analysis</role>
<role content-type="http://credit.casrai.org/">Methodology</role>
<xref ref-type="aff" rid="aff001"><sup>1</sup></xref>
</contrib>
<contrib contrib-type="author" corresp="yes" xlink:type="simple">
<name name-style="western">
<surname>Gong</surname>
<given-names>Yuping</given-names>
</name>
<role content-type="http://credit.casrai.org/">Conceptualization</role>
<role content-type="http://credit.casrai.org/">Funding acquisition</role>
<role content-type="http://credit.casrai.org/">Project administration</role>
<role content-type="http://credit.casrai.org/">Supervision</role>
<role content-type="http://credit.casrai.org/">Visualization</role>
<role content-type="http://credit.casrai.org/">Writing – original draft</role>
<role content-type="http://credit.casrai.org/">Writing – review &amp; editing</role>
<xref ref-type="aff" rid="aff001"><sup>1</sup></xref>
<xref ref-type="corresp" rid="cor001">*</xref>
</contrib>
</contrib-group>
<aff id="aff001"><label>1</label> <addr-line>Department of Hematology, West China Hospital, Sichuan University, Chengdu, Sichuan Province, China</addr-line></aff>
<aff id="aff002"><label>2</label> <addr-line>Department of Cardiology, Zhong Shan Hospital, Fu Dan University, Shanghai, China</addr-line></aff>
<aff id="aff003"><label>3</label> <addr-line>Department of Evidence-based Medicine and Clinical Epidemiology, West China Hospital, Sichuan University, Chengdu, Sichuan Province, China</addr-line></aff>
<contrib-group>
<contrib contrib-type="editor" xlink:type="simple">
<name name-style="western">
<surname>Hills</surname>
<given-names>Robert K</given-names>
</name>
<role>Editor</role>
<xref ref-type="aff" rid="edit1"/>
</contrib>
</contrib-group>
<aff id="edit1"><addr-line>Cardiff University, UNITED KINGDOM</addr-line></aff>
<author-notes>
<fn fn-type="conflict" id="coi001">
<p>The authors have declared that no competing interests exist.</p>
</fn>
<corresp id="cor001">* E-mail: <email xlink:type="simple">gongyuping2010@aliyun.com</email></corresp>
</author-notes>
<pub-date pub-type="epub">
<day>27</day>
<month>9</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="collection">
<year>2017</year>
</pub-date>
<volume>12</volume>
<issue>9</issue>
<elocation-id>e0185053</elocation-id>
<history>
<date date-type="received">
<day>19</day>
<month>4</month>
<year>2017</year>
</date>
<date date-type="accepted">
<day>6</day>
<month>9</month>
<year>2017</year>
</date>
</history>
<permissions>
<copyright-year>2017</copyright-year>
<copyright-holder>Zheng et al</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/" xlink:type="simple">
<license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/" xlink:type="simple">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p>
</license>
</permissions>
<self-uri content-type="pdf" xlink:href="info:doi/10.1371/journal.pone.0185053"/>
<abstract>
<sec id="sec001">
<title>Background</title>
<p>The recent application of gene-sequencing technology has identified many new somatic mutations in patients with myelodysplastic syndromes (MDS). Among them, <italic>serine and arginine rich splicing factor 2</italic> (<italic>SRSF2</italic>) mutations belonging to the RNA splicing pathway were of interest. Many studies have already reported the potential prognostic value of <italic>SRSF2</italic> mutations in MDS patients, with controversial results. Therefore, a meta-analysis was performed to investigate their prognostic impact on MDS.</p>
</sec>
<sec id="sec002">
<title>Methods</title>
<p>Databases, including PubMed, Embase and the Cochrane Library, were searched for relevant studies published up to 14 October 2016. Overall survival (OS) was selected as the primary endpoint, and acute myeloid leukemia (AML) transformation was the secondary endpoint. We extracted the corresponding hazard ratios (HRs) and their 95% confidence intervals (CIs) for OS and AML transformation from multivariate Cox proportional hazards models. The combined HRs with their 95% CIs were calculated using fixed or random effect models.</p>
</sec>
<sec id="sec003">
<title>Results</title>
<p>A total of 10 cohort studies, covering 1864 patients with de novo MDS and 294 patients with <italic>SRSF2</italic> mutations, were included in the final meta-analysis. Our results indicated that <italic>SRSF2</italic> mutations had an adverse prognostic impact on OS (p&lt;0.0001) and AML transformation (p = 0.0005) in the total population. Among the MDS patients with low or intermediate-1 risk defined according to the International Prognostic Scoring System (IPSS), <italic>SRSF2</italic> mutations predicted a shorter OS (p = 0.009) and were more likely to transform to AML (p = 0.007).</p>
</sec>
<sec id="sec004">
<title>Conclusions</title>
<p>This meta-analysis indicates an independent, adverse prognostic impact of <italic>SRSF2</italic> mutations on OS and AML transformation in patients with de novo MDS. This also applies to the subgroup of low- or intermediate-1-IPSS risk MDS. The identification of mutations in <italic>SRSF2</italic> can improve current risk stratification and help make treatment decisions.</p>
</sec>
</abstract>
<funding-group>
<award-group id="award001">
<funding-source>
<institution>The foundation of the Science &amp; Technology Department of Sichuan Province</institution>
</funding-source>
<award-id>No. 2015SZ0234-5</award-id>
<principal-award-recipient>
<name name-style="western">
<surname>Gong</surname>
<given-names>Yuping</given-names>
</name>
</principal-award-recipient>
</award-group>
<award-group id="award002">
<funding-source>
<institution>The foundation of Administration of traditional Chinese medicine of Sichuan Province</institution>
</funding-source>
<award-id>No. 2014A038</award-id>
<principal-award-recipient>
<name name-style="western">
<surname>Gong</surname>
<given-names>Yuping</given-names>
</name>
</principal-award-recipient>
</award-group>
<award-group id="award003">
<funding-source>
<institution>The foundation of Science and Technology Bureau of Chengdu</institution>
</funding-source>
<award-id>No. 2016-HM01-00001-SF</award-id>
<principal-award-recipient>
<name name-style="western">
<surname>Gong</surname>
<given-names>Yuping</given-names>
</name>
</principal-award-recipient>
</award-group>
<funding-statement>The work was supported by the Foundation of the Science &amp; Technology Department of Sichuan Province (No. 2015SZ0234-5), Foundation of Administration of traditional Chinese medicine of Sichuan Province (No. 2014A038) and the Foundation of Science and Technology Bureau of Chengdu (No. 2016-HM01-00001-SF), <ext-link ext-link-type="uri" xlink:href="http://www.scst.gov.cn/" xlink:type="simple">http://www.scst.gov.cn/</ext-link>. YPG received these funding. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</funding-statement>
</funding-group>
<counts>
<fig-count count="6"/>
<table-count count="1"/>
<page-count count="12"/>
</counts>
<custom-meta-group>
<custom-meta id="data-availability">
<meta-name>Data Availability</meta-name>
<meta-value>All relevant data are within the paper and its Supporting Information files.</meta-value>
</custom-meta>
</custom-meta-group>
</article-meta>
</front>
<body>
<sec id="sec005" sec-type="intro">
<title>Introduction</title>
<p>Myelodysplastic syndrome (MDS) is a group of clonal hematopoietic stem cell disorders characterized by ineffective hematopoiesis resulting in peripheral blood cytopenias and a risk of progression to acute myeloid leukemia (AML)[<xref ref-type="bibr" rid="pone.0185053.ref001">1</xref>]. The International Prognostic Scoring System (IPSS) and its revision (IPSS-R), depending mainly on bone marrow cytogenetics, marrow blast percentage and the presence of cytopenias, have been widely used as the standard for assessing prognosis and guiding treatment decisions for MDS patients[<xref ref-type="bibr" rid="pone.0185053.ref002">2</xref>,<xref ref-type="bibr" rid="pone.0185053.ref003">3</xref>]. Neither the IPSS nor the IPSS-R considers somatic mutations, though they play a significant role in the diagnosis and prognosis of leukemia. Recently, the application of whole-genome sequencing and whole-exome sequencing has led to the identification of new somatic mutations, which may provide important prognostic information in patients with MDS[<xref ref-type="bibr" rid="pone.0185053.ref004">4</xref>,<xref ref-type="bibr" rid="pone.0185053.ref005">5</xref>].</p>
<p>Through the above techniques, numerous mutations in genes encoding RNA splicing machinery, epigenetic modifiers, chromatin modifiers, transcription factors, signal transducers, RAS pathway members, cohesin complex members and DNA repair proteins have been identified in MDS[<xref ref-type="bibr" rid="pone.0185053.ref006">6</xref>]. Among them, gene mutations involved in the RNA splicing pathway are the most frequent molecular abnormalities[<xref ref-type="bibr" rid="pone.0185053.ref007">7</xref>,<xref ref-type="bibr" rid="pone.0185053.ref008">8</xref>]. RNA splicing is a process that generates mature mRNAs by excising introns and splicing exons from pre-messenger RNA (pre-mRNA); alteration of the excising and splicing of a single pre-mRNA transcript can be used to produce many different mRNAs and result in protein diversity[<xref ref-type="bibr" rid="pone.0185053.ref009">9</xref>,<xref ref-type="bibr" rid="pone.0185053.ref010">10</xref>]. The spliceosome mutations in MDS affect the major components of both the E and A splicing complexes in a mutually exclusive manner, leading to the impaired recognition of 3′-splice site recognition during pre-mRNA processing, inducing abnormally spliced mRNA species and compromising hematopoiesis[<xref ref-type="bibr" rid="pone.0185053.ref005">5</xref>].</p>
<p>One of the potential candidate genes involved in the RNA splicing pathway is <italic>serine and arginine rich splicing factor 2</italic> (<italic>SRSF2</italic>). <italic>SRSF2</italic>, located on chromosome 17q25.2, encodes a protein belonging to the serine/arginine-rich (SR) splicing regulatory factor family[<xref ref-type="bibr" rid="pone.0185053.ref011">11</xref>]. <italic>SRSF2</italic> plays a role in preventing exon skipping, ensuring the accuracy of splicing and regulating alternative pre-mRNA splicing[<xref ref-type="bibr" rid="pone.0185053.ref011">11</xref>]. Although the precise role of <italic>SRSF2</italic> mutations in leukemogenesis remains elusive, many studies have already reported the potential prognostic value of <italic>SRSF2</italic> mutations in MDS patients, with controversial results. Lin et al. [<xref ref-type="bibr" rid="pone.0185053.ref012">12</xref>] and Thol et al. [<xref ref-type="bibr" rid="pone.0185053.ref013">13</xref>] reported <italic>SRSF2</italic> mutations were significantly correlated with poor survival in patients with MDS, while others [<xref ref-type="bibr" rid="pone.0185053.ref014">14</xref>,<xref ref-type="bibr" rid="pone.0185053.ref015">15</xref>] reported no prognostic impact of <italic>SRSF2</italic> mutations. Hence, we performed a meta-analysis on data from related published studies to further explore the combined prognostic impacts of <italic>SRSF2</italic> mutations for patients with de novo MDS.</p>
</sec>
<sec id="sec006" sec-type="materials|methods">
<title>Materials and methods</title>
<sec id="sec007">
<title>Literature search</title>
<p>We conducted a literature search of several databases, including PubMed, Embase and the Cochrane Library, for potentially relevant studies published up to October 14, 2016. The following terms were used to find eligible studies: “<italic>SRSF2</italic>” or “<italic>serine and arginine rich splicing factor 2</italic>” or “SC35” and “myelodysplastic syndrome” or “MDS” or “myelodysplasia” or “preleukemia”. No language limitations were added to the search strategy. References of eligible studies were manually searched to find other potentially relevant articles.</p>
</sec>
<sec id="sec008">
<title>Inclusion and exclusion</title>
<p>Only papers that met all the following criteria were included: (1)The study focused on the prognostic impact of <italic>SRSF2</italic> mutations in de novo MDS patients; (2)The study provided sufficient survival data for patients with <italic>SRSF2</italic> mutations, at least on overall survival (OS); and (3)The study was published as a full article in English. Review articles, case reports and laboratory studies were excluded. If the same or overlapping data was presented in multiple studies, only the most recent or the highest quality study was included.</p>
<p>Two reviewers (Xue Zheng and Zhi Zhan) screened the database and identified the eligible studies, independently. Disagreements were resolved by discussion.</p>
</sec>
<sec id="sec009">
<title>Data extraction</title>
<p>Two reviewers (Xue Zheng and Duolan Naren) independently extracted relevant information from each eligible study onto a spreadsheet. The data included the first author’s name, year of publication, country of origin, number of patients, age and gender distribution of patients, criteria for classification of MDS, MDS subtype, and the distribution of patients by IPSS classification. We selected OS as the primary endpoint and AML transformation as the secondary endpoint. Endpoints for OS were defined as either deceased (failure) or alive at last follow-up, and the time to AML transformation was calculated beginning from the time the patient entered the trial to the time of AML diagnosis. We extracted the corresponding hazard ratios (HRs) and their 95% confidence intervals (CIs) for OS and AML transformation from multivariate Cox proportional hazards models to evaluate the prognostic impact of <italic>SRSF2</italic>-mutated compared with unmutated patients with MDS. If the published paper did not report the required data for analysis, we contacted the corresponding authors to obtain missing data. Disagreements between reviewers regarding data abstraction were resolved through discussion.</p>
</sec>
<sec id="sec010">
<title>Quality assessment</title>
<p>Two reviewers (Xue Zheng and Duolan Naren) independently evaluated the methodological quality of each included study. The quality of cohort studies was evaluated by the Newcastle-Ottawa quality assessment scale (NOS). The NOS includes a total of 9 points, with 4 points for selection, 2 points for comparability, and 3 points for exposure or outcome[<xref ref-type="bibr" rid="pone.0185053.ref016">16</xref>]. Cohort studies that scored six or more points were regarded to be of high quality[<xref ref-type="bibr" rid="pone.0185053.ref016">16</xref>]. Disagreements were resolved by discussion.</p>
</sec>
<sec id="sec011">
<title>Statistical analysis</title>
<p>Review Manager version 5.3 software, following the recommendation of the Cochrane Collaboration (<ext-link ext-link-type="uri" xlink:href="http://tech.cochrane.org/revman/download" xlink:type="simple">http://tech.cochrane.org/revman/download</ext-link>), was used to calculate the combined survival impact of <italic>SRSF2</italic> mutations. The prognostic effect of <italic>SRSF2</italic> mutations on OS and AML transformation was evaluated by calculation of the combined HRs and their 95% CIs with the generic inverse variance method. The result suggested statistical significance if the 95% CI did not overlap 1. Moreover, <italic>SRSF2</italic> mutations contributed an adverse survival effect compared to unmutated patients when the HR was more than 1. The heterogeneity of the studies was evaluated through the chi-squared test, with significance set at a p-value of less than 0.10. The I<sup>2</sup> statistic was used to quantify the heterogeneity. An I<sup>2</sup> value of less than 25% was regarded as low heterogeneity, a value between 25 and 50% indicated moderate heterogeneity, and a value over 50% suggested high heterogeneity[<xref ref-type="bibr" rid="pone.0185053.ref017">17</xref>]. The random effect model was used if high heterogeneity was observed; otherwise, a fixed effect model was used for the meta-analysis.</p>
<p>We used sensitivity analysis and meta-regression analysis regarding the OS of the total population to evaluate the heterogeneity between studies. Sensitivity analysis was used to assess the influence of each study on the stability of the pooled results by sequential omission of one study at a time. Meta-regression analysis was used to evaluate the possible influence of publication year or study country on outcome when there were 10 or more studies including outcome. Funnel plots, Begg’s tests and Egger’s tests were used to screen for potential publication bias regarding the OS of the total population[<xref ref-type="bibr" rid="pone.0185053.ref018">18</xref>,<xref ref-type="bibr" rid="pone.0185053.ref019">19</xref>]. The calculations were carried out in Stata version 12.0 software (Stata Corp, College Station, TX, USA) with a p-value less than 0.05 being considered significant.</p>
</sec>
</sec>
<sec id="sec012" sec-type="results">
<title>Results</title>
<sec id="sec013">
<title>Study identification and selection</title>
<p>As shown in <xref ref-type="fig" rid="pone.0185053.g001">Fig 1</xref>, the initial search revealed 484 studies. After exclusion of 93 duplicates, 391 citations were further reviewed by reading the titles and abstracts, and 316 citations were then excluded for irrelevant article type or irrelevant subject. A total of 75 studies were left for full text review. Among them, 55 studies were excluded as conference abstracts, and 11 were further excluded because they did not evaluate outcome or did not provide sufficient data. During revision, one additional citation was reviewed and included in the final meta-analysis, leaving a total of 10 citations[<xref ref-type="bibr" rid="pone.0185053.ref012">12</xref>–<xref ref-type="bibr" rid="pone.0185053.ref015">15</xref>, <xref ref-type="bibr" rid="pone.0185053.ref020">20</xref>–<xref ref-type="bibr" rid="pone.0185053.ref025">25</xref>](<xref ref-type="fig" rid="pone.0185053.g001">Fig 1</xref>).</p>
<fig id="pone.0185053.g001" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0185053.g001</object-id>
<label>Fig 1</label>
<caption>
<title>Flow diagram of study selection.</title>
</caption>
<graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pone.0185053.g001" xlink:type="simple"/>
</fig>
</sec>
<sec id="sec014">
<title>Characteristics of included studies</title>
<p>The 10 included studies were all cohort studies and were published between 2012 and 2016 (<xref ref-type="table" rid="pone.0185053.t001">Table 1</xref>). They were conducted in East Asia, Europe or North America. The studies included a total of 1864 patients with MDS, in which 294 patients harbored a mutation in SRSF2. For one study that included patients with both MDS and AML[<xref ref-type="bibr" rid="pone.0185053.ref023">23</xref>], only patients with MDS were studied in the meta-analysis. Occurrence of mutations of SRSF2 varied between 4.3% and 15% in MDS patients and were more frequent in chronic myelomonocytic leukemia (CMML) (29%-46%).</p>
<table-wrap id="pone.0185053.t001" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0185053.t001</object-id>
<label>Table 1</label> <caption><title>Characteristics of studies included in the meta-analysis.</title></caption>
<alternatives>
<graphic id="pone.0185053.t001g" mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pone.0185053.t001" xlink:type="simple"/>
<table>
<colgroup>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
</colgroup>
<thead>
<tr>
<th align="left"/>
<th align="left"/>
<th align="left"/>
<th align="left"/>
<th align="left"/>
<th align="right">MDS<break/>Subtype</th>
<th align="left"/>
<th align="left"/>
<th align="left"/>
<th align="right"/>
<th align="right">MDS</th>
<th align="right">IPSS</th>
<th align="left"/>
<th align="left"/>
</tr>
<tr>
<th align="left">Study</th>
<th align="left">Country</th>
<th align="left">n/N</th>
<th align="left">Age(years)</th>
<th align="left">Sex(M/F)</th>
<th align="left">RA/RCUD<break/>/RARS</th>
<th align="left">RAEB/<break/>RAEB-t</th>
<th align="left">RCMD/<break/>RCMD-RS</th>
<th align="left">CMML</th>
<th align="left">Others</th>
<th align="left">criteria</th>
<th align="left">Low+Int1/Int2+<break/>High/Unknown</th>
<th align="left">Adjustments</th>
<th align="left">NOS</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left">Wu</td>
<td align="left">China</td>
<td align="left">13/304</td>
<td align="left">57(11,89)<xref ref-type="table-fn" rid="t001fn002">*</xref></td>
<td align="left">162/142</td>
<td align="left">0/20/9</td>
<td align="left">123/0</td>
<td align="left">0/145</td>
<td align="left">0</td>
<td align="left">7</td>
<td align="left">WHO</td>
<td align="left">212/90/2</td>
<td align="left">1,2,5,6,7</td>
<td align="left">9</td>
</tr>
<tr>
<td align="left">2016</td>
<td align="left"/>
<td align="left"/>
<td align="left"/>
<td align="left"/>
<td align="left"/>
<td align="left"/>
<td align="left"/>
<td align="left"/>
<td align="left"/>
<td align="left"/>
<td align="left"/>
<td align="left"/>
<td align="left"/>
</tr>
<tr>
<td align="left">Cui</td>
<td align="left">China</td>
<td align="left">42/145</td>
<td align="left">63(18,85)<xref ref-type="table-fn" rid="t001fn002">*</xref></td>
<td align="left">98/47</td>
<td align="left">0/0/0</td>
<td align="left">0/0</td>
<td align="left">0/0</td>
<td align="left">145</td>
<td align="left">0</td>
<td align="left">WHO</td>
<td align="left">NR</td>
<td align="left">NR</td>
<td align="left">8</td>
</tr>
<tr>
<td align="left">2015</td>
<td align="left"/>
<td align="left"/>
<td align="left"/>
<td align="left"/>
<td align="left"/>
<td align="left"/>
<td align="left"/>
<td align="left"/>
<td align="left"/>
<td align="left"/>
<td align="left"/>
<td align="left"/>
<td align="left"/>
</tr>
<tr>
<td align="left">Kim</td>
<td align="left">Korea</td>
<td align="left">5/52</td>
<td align="left">52(18,73)<xref ref-type="table-fn" rid="t001fn002">*</xref></td>
<td align="left">36/16</td>
<td align="left">2/0/1</td>
<td align="left">27/0</td>
<td align="left">20/0</td>
<td align="left">0</td>
<td align="left">2</td>
<td align="left">WHO</td>
<td align="left">22/30/0</td>
<td align="left">6,7</td>
<td align="left">7</td>
</tr>
<tr>
<td align="left">2015</td>
<td align="left"/>
<td align="left"/>
<td align="left"/>
<td align="left"/>
<td align="left"/>
<td align="left"/>
<td align="left"/>
<td align="left"/>
<td align="left"/>
<td align="left"/>
<td align="left"/>
<td align="left"/>
<td align="left"/>
</tr>
<tr>
<td align="left">Kang</td>
<td align="left">Korea</td>
<td align="left">13/129</td>
<td align="left">63.7±12.4<xref ref-type="table-fn" rid="t001fn003">#</xref></td>
<td align="left">71/58</td>
<td align="left">0/19/0</td>
<td align="left">46/0</td>
<td align="left">56/0</td>
<td align="left">0</td>
<td align="left">8</td>
<td align="left">WHO</td>
<td align="left">NR</td>
<td align="left">1,2,4,7</td>
<td align="left">8</td>
</tr>
<tr>
<td align="left">2015</td>
<td align="left"/>
<td align="left"/>
<td align="left"/>
<td align="left"/>
<td align="left"/>
<td align="left"/>
<td align="left"/>
<td align="left"/>
<td align="left"/>
<td align="left"/>
<td align="left"/>
<td align="left"/>
<td align="left"/>
</tr>
<tr>
<td align="left">Karimi</td>
<td align="left">Sweden</td>
<td align="left">15/100</td>
<td align="left">72(32,88)<xref ref-type="table-fn" rid="t001fn002">*</xref></td>
<td align="left">51/49</td>
<td align="left">0/0/10</td>
<td align="left">41/0</td>
<td align="left">2/11</td>
<td align="left">15</td>
<td align="left">21</td>
<td align="left">WHO</td>
<td align="left">NR</td>
<td align="left">1,2,4,7</td>
<td align="left">8</td>
</tr>
<tr>
<td align="left">2015</td>
<td align="left"/>
<td align="left"/>
<td align="left"/>
<td align="left"/>
<td align="left"/>
<td align="left"/>
<td align="left"/>
<td align="left"/>
<td align="left"/>
<td align="left"/>
<td align="left"/>
<td align="left"/>
<td align="left"/>
</tr>
<tr>
<td align="left">Lin</td>
<td align="left">China</td>
<td align="left">5/108</td>
<td align="left">60(20,86)<xref ref-type="table-fn" rid="t001fn002">*</xref></td>
<td align="left">64/45</td>
<td align="left">10/0/0</td>
<td align="left">48/0</td>
<td align="left">36/8</td>
<td align="left">0</td>
<td align="left">6</td>
<td align="left">WHO</td>
<td align="left">72/32/4</td>
<td align="left">1,2,3,5,7</td>
<td align="left">9</td>
</tr>
<tr>
<td align="left">2014</td>
<td align="left"/>
<td align="left"/>
<td align="left"/>
<td align="left"/>
<td align="left"/>
<td align="left"/>
<td align="left"/>
<td align="left"/>
<td align="left"/>
<td align="left"/>
<td align="left"/>
<td align="left"/>
<td align="left"/>
</tr>
<tr>
<td align="left">Itzykson</td>
<td align="left">France</td>
<td align="left">101/312</td>
<td align="left">74(41,93)<xref ref-type="table-fn" rid="t001fn002">*</xref></td>
<td align="left">210/102</td>
<td align="left">0/0/0</td>
<td align="left">0/0</td>
<td align="left">0/0</td>
<td align="left">312</td>
<td align="left">0</td>
<td align="left">WHO</td>
<td align="left">NR</td>
<td align="left">7</td>
<td align="left">7</td>
</tr>
<tr>
<td align="left">2013</td>
<td align="left"/>
<td align="left"/>
<td align="left"/>
<td align="left"/>
<td align="left"/>
<td align="left"/>
<td align="left"/>
<td align="left"/>
<td align="left"/>
<td align="left"/>
<td align="left"/>
<td align="left"/>
<td align="left"/>
</tr>
<tr>
<td align="left">Thol</td>
<td align="left">Germany</td>
<td align="left">24/193</td>
<td align="left">NR(36,92)<xref ref-type="table-fn" rid="t001fn002">*</xref></td>
<td align="left">119/74</td>
<td align="left">38/0/20</td>
<td align="left">53/0</td>
<td align="left">21/9</td>
<td align="left">0</td>
<td align="left">52</td>
<td align="left">WHO</td>
<td align="left">96/51/43</td>
<td align="left">1,3,7</td>
<td align="left">8</td>
</tr>
<tr>
<td align="left">2012</td>
<td align="left"/>
<td align="left"/>
<td align="left"/>
<td align="left"/>
<td align="left"/>
<td align="left"/>
<td align="left"/>
<td align="left"/>
<td align="left"/>
<td align="left"/>
<td align="left"/>
<td align="left"/>
<td align="left"/>
</tr>
<tr>
<td align="left">Wu</td>
<td align="left">China</td>
<td align="left">34/233</td>
<td align="left">66(18,95)<xref ref-type="table-fn" rid="t001fn002">*</xref></td>
<td align="left">161/72</td>
<td align="left">98</td>
<td align="left">102</td>
<td align="left">0/0</td>
<td align="left">33</td>
<td align="left">0</td>
<td align="left">FAB</td>
<td align="left">115/99/19</td>
<td align="left">1,3,7</td>
<td align="left">8</td>
</tr>
<tr>
<td align="left">2012</td>
<td align="left"/>
<td align="left"/>
<td align="left"/>
<td align="left"/>
<td align="left"/>
<td align="left"/>
<td align="left"/>
<td align="left"/>
<td align="left"/>
<td align="left"/>
<td align="left"/>
<td align="left"/>
<td align="left"/>
</tr>
<tr>
<td align="left">Bejar</td>
<td align="left">USA</td>
<td align="left">42/288</td>
<td align="left">69(15,90)<xref ref-type="table-fn" rid="t001fn002">*</xref></td>
<td align="left">203/85</td>
<td align="left">173/0/41</td>
<td align="left">71/3<xref ref-type="table-fn" rid="t001fn004">※</xref></td>
<td align="left">0/0</td>
<td align="left">0</td>
<td align="left">0</td>
<td align="left">FAB</td>
<td align="left">288/0/0</td>
<td align="left">1,2,3,7</td>
<td align="left">8</td>
</tr>
<tr>
<td align="left">2012</td>
<td align="left"/>
<td align="left"/>
<td align="left"/>
<td align="left"/>
<td align="left"/>
<td align="left"/>
<td align="left"/>
<td align="left"/>
<td align="left"/>
<td align="left"/>
<td align="left"/>
<td align="left"/>
<td align="left"/>
</tr>
</tbody>
</table>
</alternatives>
<table-wrap-foot>
<fn id="t001fn001"><p>Abbreviations: CMML, chronic myelomonocytic leukemia; FAB, French American British classification; IPSS, International Prognostic Scoring System; MDS, myelodysplastic syndromes; n, number of patients with SRSF2 mutations; N, number of patients in total; NOS, Newcastle-Ottawa quality assessment scale; NR, not reported; RA, refractory anemia; RARS, RA with ringed sideroblasts; RAEB, RA with excess blasts; RAEB-t, RAEB in transformation; RCMD, refractory cytopenia with multilineage dysplasia; RCMD-RS, refractory cytopenia with multilineage dysplasia and ringed sideroblasts; RCUD, refractory cytopenia with unilineage dysplasia; WHO, World Health Organization.</p></fn>
<fn id="t001fn002"><p>*, median age (range)</p></fn>
<fn id="t001fn003"><p>#, mean age ± SD</p></fn>
<fn id="t001fn004"><p>※, the 3 patients with RAEB-t had circulating blasts but≤10% blasts in the bone marrow.</p></fn>
<fn id="t001fn005"><p>Main adjusted variables in multivariate Cox proportional hazards models: 1 = age; 2 = sex; 3 = IPSS; 4 = IPSS-R; 5 = neutrophils; 6 = hemoglobin; 7 = mutation status</p></fn>
</table-wrap-foot>
</table-wrap>
<p>In addition, we managed to contact the authors for some unpublished data. Kim et al. offered the HRs and their 95% CIs for OS after initial treatment of the MDS patients with <italic>SRSF2</italic> mutations in their multivariate cox regression analysis. Similarly, Cui et al. and Bejar et al. also offered the HRs and their 95% CIs for OS in the same setting.</p>
</sec>
<sec id="sec015">
<title>Quality assessment of included studies</title>
<p>As shown in <xref ref-type="table" rid="pone.0185053.t001">Table 1</xref>, the mean overall NOS score was 8 (range 7–9), indicating that the quality of included studies was high.</p>
</sec>
<sec id="sec016">
<title>Clinical characteristics of MDS patients with <italic>SRSF2</italic> mutations</title>
<p>Patients carrying <italic>SRSF2</italic> mutations were older than those with unmutated <italic>SRSF2</italic>[<xref ref-type="bibr" rid="pone.0185053.ref012">12</xref>,<xref ref-type="bibr" rid="pone.0185053.ref014">14</xref>,<xref ref-type="bibr" rid="pone.0185053.ref015">15</xref>,<xref ref-type="bibr" rid="pone.0185053.ref021">21</xref>,<xref ref-type="bibr" rid="pone.0185053.ref025">25</xref>], and <italic>SRSF2</italic> mutations were significantly associated with old age (p&lt;0.05)[<xref ref-type="bibr" rid="pone.0185053.ref014">14</xref>,<xref ref-type="bibr" rid="pone.0185053.ref015">15</xref>,<xref ref-type="bibr" rid="pone.0185053.ref021">21</xref>]. Patients with mutations in <italic>SRSF2</italic> had an increased incidence of <italic>RUNX1</italic>, <italic>TET2</italic>, <italic>IDH1</italic>, <italic>IDH2</italic> and <italic>ASXL1</italic> mutations[<xref ref-type="bibr" rid="pone.0185053.ref013">13</xref>,<xref ref-type="bibr" rid="pone.0185053.ref015">15</xref>,<xref ref-type="bibr" rid="pone.0185053.ref021">21</xref>,<xref ref-type="bibr" rid="pone.0185053.ref024">24</xref>].</p>
</sec>
<sec id="sec017">
<title>Analysis of outcomes</title>
<p>As shown in <xref ref-type="fig" rid="pone.0185053.g002">Fig 2</xref>, the meta-analysis of the effect of <italic>SRSF2</italic> mutations on OS in MDS patients was performed for all cohort studies. Our results indicated that the presence of <italic>SRSF2</italic> mutations was an independent adverse prognostic factor for OS (HR = 1.49, 95% CI: 1.23–1.79, with a p-value less than 0.0001) with a low heterogeneity (I<sup>2</sup> = 2%). Three studies reported data on AML transformation, with 634 patients and 138 with <italic>SRSF2</italic> mutations (<xref ref-type="fig" rid="pone.0185053.g003">Fig 3</xref>). The pooled HR for AML transformation was 1.89 (95% CI: 1.32–2.71, with a p-value of 0.0005, I<sup>2</sup> = 0%) for <italic>SRSF2</italic>-mutated patients compared with unmutated patients, revealing that patients with <italic>SRSF2</italic> mutations have a more rapid and frequent transformation to AML. There was no heterogeneity among the analyzed studies (I<sup>2</sup> = 0%).</p>
<fig id="pone.0185053.g002" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0185053.g002</object-id>
<label>Fig 2</label>
<caption>
<title>Forest plots of pooled HRs and 95% CIs for OS assessing the prognostic value of <italic>SRSF2</italic> mutations in the cohort of MDS patients.</title>
</caption>
<graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pone.0185053.g002" xlink:type="simple"/>
</fig>
<fig id="pone.0185053.g003" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0185053.g003</object-id>
<label>Fig 3</label>
<caption>
<title>Forest plots of pooled HRs and 95% CIs for AML transformation assessing the prognostic value of <italic>SRSF2</italic> mutations in the cohort of MDS patients.</title>
</caption>
<graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pone.0185053.g003" xlink:type="simple"/>
</fig>
<p>Several studies focused on patients with low- or intermediate-1-IPSS risk MDS harboring <italic>SRSF2</italic> mutations. The pooled HR for OS was 1.50 (95% CI: 1.11–2.03, with a p-value of 0.009, I<sup>2</sup> = 0%), and the HR for AML transformation was 3.12 (95% CI: 1.36–7.11, with a p-value of 0.007, I<sup>2</sup> = 0%) for patients with low- or intermediate-1-IPSS risk MDS with <italic>SRSF2</italic> mutations, compared to <italic>SRSF2</italic>-unmutated patients (<xref ref-type="fig" rid="pone.0185053.g004">Fig 4</xref>), indicating that <italic>SRSF2</italic> mutations predicted an independent unfavorable prognostic impact in terms of both OS and AML transformation. Our results showed no heterogeneity among these studies (I<sup>2</sup> = 0%).</p>
<fig id="pone.0185053.g004" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0185053.g004</object-id>
<label>Fig 4</label>
<caption>
<title/>
<p>Forest plots of pooled HRs and 95% CIs assessing the prognostic value of <italic>SRSF2</italic> mutations in patients with low- or intermediate-1-IPSS risk MDS for: (A) OS and (B) AML transformation.</p>
</caption>
<graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pone.0185053.g004" xlink:type="simple"/>
</fig>
<p>Among several studies, <italic>SRSF2</italic> mutations were strongly associated with older age[<xref ref-type="bibr" rid="pone.0185053.ref014">14</xref>,<xref ref-type="bibr" rid="pone.0185053.ref015">15</xref>,<xref ref-type="bibr" rid="pone.0185053.ref021">21</xref>]. We further performed a subgroup analysis, examining whether <italic>SRSF2</italic> mutations could still predict prognosis after adjusting for age. The meta-analysis of <italic>SRSF2</italic> mutations after adjustment for age in COX multivariable models was carried out for 7 cohort studies, with 1355 patients and 146 with <italic>SRSF2</italic> mutations (<xref ref-type="fig" rid="pone.0185053.g005">Fig 5</xref>). In this population, patients with <italic>SRSF2</italic> mutations had a significantly shorter OS compared to unmutated patients (HR = 1.62, 95% CI: 1.29–2.03, with a p-value less than 0.0001), with no heterogeneity shown by I<sup>2</sup> testing (I<sup>2</sup> = 0%).</p>
<fig id="pone.0185053.g005" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0185053.g005</object-id>
<label>Fig 5</label>
<caption>
<title>Forest plots of pooled HRs and 95% CIs for OS assessing the prognostic value of <italic>SRSF2</italic> mutations in MDS patients after adjusting for age in COX multivariable models.</title>
</caption>
<graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pone.0185053.g005" xlink:type="simple"/>
</fig>
</sec>
<sec id="sec018">
<title>Sensitivity analysis, meta-regression, and publication bias</title>
<p>We conducted a sensitivity analysis by excluding one study at a time from the meta-analysis, examining the effect of individual studies on the combined HR. The result indicated that there were no significant effects of individual studies on the combined HR for OS in the total population. Meta-regression analysis showed no significant correlations between the publication year or the study country and OS in all patients. There was no significant publication bias in the funnel plot of OS of all population, which contained all 10 studies (<xref ref-type="fig" rid="pone.0185053.g006">Fig 6</xref>). The results of Begg’s test and Egger’s test also suggested no publication bias (p = 0.858 of Begg’s test and p = 0.774 of Egger’s test)</p>
<fig id="pone.0185053.g006" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0185053.g006</object-id>
<label>Fig 6</label>
<caption>
<title>Funnel plots of publication bias for OS of all patients.</title>
</caption>
<graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pone.0185053.g006" xlink:type="simple"/>
</fig>
</sec>
</sec>
<sec id="sec019" sec-type="conclusions">
<title>Discussion</title>
<p>The pooled meta-analysis of included studies demonstrated that patients with <italic>SRSF2</italic> mutations had a worse outcome than unmutated patients in the total population, with a shorter OS and a more rapid and frequent transformation to AML. These mutations were also correlated with adverse outcomes in OS and AML transformation in the subgroup of low- or intermediate-1-IPSS risk patients. MDS is a heterogeneous disease with various clinical outcomes, thus, an accurate prediction of prognosis is crucial for selecting the appropriate treatment. Many patients with low- or intermediate-1-IPSS risk MDS have a more aggressive clinical course and an inferior OS than expected. This may be because neither the IPSS nor the IPSS-R takes into account gene mutations, which can provide prognostic information that is not captured by the IPSS and its revision. Our meta-analysis suggested that <italic>SRSF2</italic> mutations were an independent molecular marker for shorter survival and AML transformation in the subgroup of low- or intermediate-1-IPSS risk MDS patients. A combination of <italic>SRSF2</italic> status and IPSS assessment might improve prognostic evaluation for patients with low- or intermediate-1-IPSS risk MDS, and patients with <italic>SRSF2</italic> mutations might benefit from more intensive treatment. However, this analysis is limited by the small number of included studies. More studies concerning <italic>SRSF2</italic> mutations in this subgroup are needed to further verify or modify the results of the pooled analysis.</p>
<p>Increasing age is a well-known significant prognostic factor for survival in MDS patients[<xref ref-type="bibr" rid="pone.0185053.ref003">3</xref>], and our included studies demonstrated that MDS patents with <italic>SRSF2</italic> mutations were of older age compared with unmutated patients. Wu et al. [<xref ref-type="bibr" rid="pone.0185053.ref015">15</xref>] found that the poor prognostic impact of <italic>SRSF2</italic> mutations on OS might be explained by their close association with old age. Our meta-analysis suggested that <italic>SRSF2</italic> mutations still had a significantly poor prognostic effect on OS after adjusting for the effect of age. Thus, mutations in <italic>SRSF2</italic> provide independent prognostic information, which can not be attributed to old age.</p>
<p>Although the precise mechanisms of the contributions of <italic>SRSF2</italic> mutations to the pathogenesis of MDS remain largely unknown, a growing number of studies have explained the mechanisms of <italic>SRSF2</italic> mutations leading to the poor prognosis of MDS patients: (1) <italic>SRSF2</italic> mutations occur early and are implicated as founder mutations in MDS[<xref ref-type="bibr" rid="pone.0185053.ref008">8</xref>,<xref ref-type="bibr" rid="pone.0185053.ref026">26</xref>], suggesting that they may play an important role in disease initiation. (2) <italic>SRSF2</italic> mutations alter normal sequence-specific RNA binding activity, therefore altering the recognition of specific exonic splicing enhancer motifs to drive recurrent mis-splicing of key hematopoietic regulators[<xref ref-type="bibr" rid="pone.0185053.ref027">27</xref>]. Evidence from a study using an <italic>SRSF2</italic> knock-in mouse model demonstrates that <italic>SRSF2</italic> mutations can impair differentiation and increase apoptosis, resulting in peripheral cytopenias and morphologic dysplasia[<xref ref-type="bibr" rid="pone.0185053.ref027">27</xref>]. (3) <italic>SRSF2</italic> has a critical role in maintaining genomic stability and regulating cell proliferation[<xref ref-type="bibr" rid="pone.0185053.ref028">28</xref>]. Depletion of <italic>SRSF2</italic> can cause genomic instability, which may be a potential mechanism for acquiring other gene mutations during disease progression to induce AML transformation [<xref ref-type="bibr" rid="pone.0185053.ref028">28</xref>]. Yoshida et al. reported that approximately 20% of MDS cases have no known genetic changes, thus, <italic>SRSF2</italic> mutations can not fully account for the pathogenesis of MDS[<xref ref-type="bibr" rid="pone.0185053.ref005">5</xref>]. Apart from the studies showing the above mechanisms, further studies are needed to sufficiently explain the contribution of <italic>SRSF2</italic> mutations to MDS.</p>
<p>Our paper is the first meta-analysis concerning the controversial prognostic value of <italic>SRSF2</italic> mutations in MDS patients. However, several limitations should be acknowledged. First, the adjusted factors from multivariate Cox proportional hazard models in each eligible study were different, which might represent methodological heterogeneity among the 10 studies. Second, there was much clinical heterogeneity between studies, such as the diverse treatment programs, age and gender distribution of patients, MDS subtype, cytogenetic and molecular abnormalities, time of follow-up, and the methods of gene sequencing, and this heterogeneity potentially effected clinical outcomes. Third, as <italic>SRSF2</italic> mutations coexist with other mutations, such as mutations of <italic>RUNX1</italic>, <italic>TET2</italic>, <italic>IDH1</italic>, <italic>IDH2</italic> and <italic>ASXL1</italic>, we could not evaluate the potential effects of gene-gene interactions on survival outcome. Finally, although Begg’s test and Egger’s test results suggested that no publication bias was observed, it still existed due to our using only published articles.</p>
<p>In conclusion, our meta-analysis indicates an independent, adverse prognostic impact of <italic>SRSF2</italic> mutations on OS and AML transformation in patients with de novo MDS. This also applies to the subgroup of low- or intermediate-1-IPSS risk MDS. In addition, the inferior OS of patients with <italic>SRSF2</italic> mutations could not be attributed to the close association of the mutation with old age. Mutations in <italic>SRSF2</italic> can provide prognostic information that is not captured by the IPSS and might improve current risk stratification and treatment decisions. A better understanding of splicing mutations is leading to the development of spliceosome inhibitors, which could provide novel targeted therapies for patients[<xref ref-type="bibr" rid="pone.0185053.ref029">29</xref>]. Further studies using prospective randomized controlled trials are needed to confirm the prognostic impact of <italic>SRSF2</italic> mutations, especially in patients with low- or intermediate-1-IPSS risk MDS.</p>
</sec>
<sec id="sec020">
<title>Supporting information</title>
<supplementary-material id="pone.0185053.s001" mimetype="application/pdf" position="float" xlink:href="info:doi/10.1371/journal.pone.0185053.s001" xlink:type="simple">
<label>S1 Checklist</label>
<caption>
<title>PRISMA checklist.</title>
<p>(PDF)</p>
</caption>
</supplementary-material>
<supplementary-material id="pone.0185053.s002" mimetype="application/pdf" position="float" xlink:href="info:doi/10.1371/journal.pone.0185053.s002" xlink:type="simple">
<label>S1 Protocol</label>
<caption>
<title>The protocol registered on the PROSPERO.</title>
<p>(PDF)</p>
</caption>
</supplementary-material>
</sec>
</body>
<back>
<ack>
<p>We sincerely thank Pu Kuang and Jianli Zhao for advices of statistical analysis.</p>
</ack>
<ref-list>
<title>References</title>
<ref id="pone.0185053.ref001"><label>1</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Ades</surname> <given-names>L</given-names></name>, <name name-style="western"><surname>Itzykson</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Fenaux</surname> <given-names>P</given-names></name>. <article-title>Myelodysplastic syndromes</article-title>. <source>Lancet</source>. <year>2014</year>; <volume>383</volume>: <fpage>2239</fpage>–<lpage>2252</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/S0140-6736(13)61901-7" xlink:type="simple">10.1016/S0140-6736(13)61901-7</ext-link></comment> <object-id pub-id-type="pmid">24656536</object-id></mixed-citation></ref>
<ref id="pone.0185053.ref002"><label>2</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Greenberg</surname> <given-names>P</given-names></name>, <name name-style="western"><surname>Cox</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>LeBeau</surname> <given-names>MM</given-names></name>, <name name-style="western"><surname>Fenaux</surname> <given-names>P</given-names></name>, <name name-style="western"><surname>Morel</surname> <given-names>P</given-names></name>, <name name-style="western"><surname>Sanz</surname> <given-names>G</given-names></name>, <etal>et al</etal>. <article-title>International scoring system for evaluating prognosis in myelodysplastic syndromes</article-title>. <source>Blood</source>. <year>1997</year>; <volume>89</volume>: <fpage>2079</fpage>–<lpage>2088</lpage>. <object-id pub-id-type="pmid">9058730</object-id></mixed-citation></ref>
<ref id="pone.0185053.ref003"><label>3</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Greenberg</surname> <given-names>PL</given-names></name>, <name name-style="western"><surname>Tuechler</surname> <given-names>H</given-names></name>, <name name-style="western"><surname>Schanz</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Sanz</surname> <given-names>G</given-names></name>, <name name-style="western"><surname>Garcia-Manero</surname> <given-names>G</given-names></name>, <name name-style="western"><surname>Solé</surname> <given-names>F</given-names></name>, <etal>et al</etal>. <article-title>Revised international prognostic scoring system for myelodysplastic syndromes</article-title>. <source>Blood</source>. <year>2012</year>; <volume>120</volume>: <fpage>2454</fpage>–<lpage>2465</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1182/blood-2012-03-420489" xlink:type="simple">10.1182/blood-2012-03-420489</ext-link></comment> <object-id pub-id-type="pmid">22740453</object-id></mixed-citation></ref>
<ref id="pone.0185053.ref004"><label>4</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Walter</surname> <given-names>MJ</given-names></name>, <name name-style="western"><surname>Shen</surname> <given-names>D</given-names></name>, <name name-style="western"><surname>Shao</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Ding</surname> <given-names>L</given-names></name>, <name name-style="western"><surname>White</surname> <given-names>BS</given-names></name>, <name name-style="western"><surname>Kandoth</surname> <given-names>C</given-names></name>, <etal>et al</etal>. <article-title>Clonal diversity of recurrently mutated genes in myelodysplastic syndromes</article-title>. <source>Leukemia</source>. <year>2013</year>; <volume>27</volume>: <fpage>1275</fpage>–<lpage>1282</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1038/leu.2013.58" xlink:type="simple">10.1038/leu.2013.58</ext-link></comment> <object-id pub-id-type="pmid">23443460</object-id></mixed-citation></ref>
<ref id="pone.0185053.ref005"><label>5</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Yoshida</surname> <given-names>K</given-names></name>, <name name-style="western"><surname>Sanada</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Shiraishi</surname> <given-names>Y</given-names></name>, <name name-style="western"><surname>Nowak</surname> <given-names>D</given-names></name>, <name name-style="western"><surname>Nagata</surname> <given-names>Y</given-names></name>, <name name-style="western"><surname>Yamamoto</surname> <given-names>R</given-names></name>, <etal>et al</etal>. <article-title>Frequent pathway mutations of splicing machinery in myelodysplasia</article-title>. <source>Nature</source>. <year>2011</year>; <volume>478</volume>: <fpage>64</fpage>–<lpage>69</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1038/nature10496" xlink:type="simple">10.1038/nature10496</ext-link></comment> <object-id pub-id-type="pmid">21909114</object-id></mixed-citation></ref>
<ref id="pone.0185053.ref006"><label>6</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Ganguly</surname> <given-names>BB</given-names></name>, <name name-style="western"><surname>Kadam</surname> <given-names>NN</given-names></name>. <article-title>Mutations of myelodysplastic syndromes (MDS): An update</article-title>. <source>Mutat Res Rev Mutat Res</source>. <year>2016</year>; <volume>769</volume>: <fpage>47</fpage>–<lpage>62</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.mrrev.2016.04.009" xlink:type="simple">10.1016/j.mrrev.2016.04.009</ext-link></comment> <object-id pub-id-type="pmid">27543316</object-id></mixed-citation></ref>
<ref id="pone.0185053.ref007"><label>7</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Damm</surname> <given-names>F</given-names></name>, <name name-style="western"><surname>Kosmider</surname> <given-names>O</given-names></name>, <name name-style="western"><surname>Gelsi-Boyer</surname> <given-names>V</given-names></name>, <name name-style="western"><surname>Renneville</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Carbuccia</surname> <given-names>N</given-names></name>, <name name-style="western"><surname>Hidalgo-Curtis</surname> <given-names>C</given-names></name>, <etal>et al</etal>. <article-title>Mutations affecting mRNA splicing define distinct clinical phenotypes and correlate with patient outcome in myelodysplastic syndromes</article-title>. <source>Blood</source>. <year>2012</year>; <volume>119</volume>: <fpage>3211</fpage>–<lpage>3218</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1182/blood-2011-12-400994" xlink:type="simple">10.1182/blood-2011-12-400994</ext-link></comment> <object-id pub-id-type="pmid">22343920</object-id></mixed-citation></ref>
<ref id="pone.0185053.ref008"><label>8</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Papaemmanuil</surname> <given-names>E</given-names></name>, <name name-style="western"><surname>Gerstung</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Malcovati</surname> <given-names>L</given-names></name>, <name name-style="western"><surname>Tauro</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Gundem</surname> <given-names>G</given-names></name>, <name name-style="western"><surname>Van Loo</surname> <given-names>P</given-names></name>, <etal>et al</etal>. <article-title>Clinical and biological implications of driver mutations in myelodysplastic syndromes</article-title>. <source>Blood</source>. <year>2013</year>; <volume>122</volume>: <fpage>3616</fpage>–<lpage>3627</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1182/blood-2013-08-518886" xlink:type="simple">10.1182/blood-2013-08-518886</ext-link></comment> <object-id pub-id-type="pmid">24030381</object-id></mixed-citation></ref>
<ref id="pone.0185053.ref009"><label>9</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Hoskins</surname> <given-names>AA</given-names></name>, <name name-style="western"><surname>Moore</surname> <given-names>MJ</given-names></name>. <article-title>The spliceosome: a flexible, reversible macromolecular machine</article-title>. <source>Trends Biochem Sci</source>. <year>2012</year>; <volume>37</volume>: <fpage>179</fpage>–<lpage>188</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.tibs.2012.02.009" xlink:type="simple">10.1016/j.tibs.2012.02.009</ext-link></comment> <object-id pub-id-type="pmid">22480731</object-id></mixed-citation></ref>
<ref id="pone.0185053.ref010"><label>10</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Boultwood</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Dolatshad</surname> <given-names>H</given-names></name>, <name name-style="western"><surname>Varanasi</surname> <given-names>SS</given-names></name>, <name name-style="western"><surname>Yip</surname> <given-names>BH</given-names></name>, <name name-style="western"><surname>Pellagatti</surname> <given-names>A</given-names></name>. <article-title>The role of splicing factor mutations in the pathogenesis of the myelodysplastic syndromes</article-title>. <source>Adv Biol Regul</source>. <year>2014</year>; <volume>54</volume>: <fpage>153</fpage>–<lpage>161</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.jbior.2013.09.005" xlink:type="simple">10.1016/j.jbior.2013.09.005</ext-link></comment> <object-id pub-id-type="pmid">24080589</object-id></mixed-citation></ref>
<ref id="pone.0185053.ref011"><label>11</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Maciejewski</surname> <given-names>JP</given-names></name>, <name name-style="western"><surname>Padgett</surname> <given-names>RA</given-names></name>. <article-title>Defects in spliceosomal machinery: a new pathway of leukaemogenesis</article-title>. <source>Br J Haematol</source>. <year>2012</year>; <volume>158</volume>: <fpage>165</fpage>–<lpage>173</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1111/j.1365-2141.2012.09158.x" xlink:type="simple">10.1111/j.1365-2141.2012.09158.x</ext-link></comment> <object-id pub-id-type="pmid">22594801</object-id></mixed-citation></ref>
<ref id="pone.0185053.ref012"><label>12</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Lin</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Yang</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Wen</surname> <given-names>XM</given-names></name>, <name name-style="western"><surname>Yang</surname> <given-names>L</given-names></name>, <name name-style="western"><surname>Deng</surname> <given-names>ZQ</given-names></name>, <name name-style="western"><surname>Qian</surname> <given-names>Z</given-names></name>, <etal>et al</etal>. <article-title>Detection of SRSF2-P95 mutation by high-resolution melting curve analysis and its effect on prognosis in myelodysplastic syndrome</article-title>. <source>PLoS One</source>. <year>2014</year>; <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1371/journal.pone.0115693" xlink:type="simple">10.1371/journal.pone.0115693</ext-link></comment> <object-id pub-id-type="pmid">25541999</object-id></mixed-citation></ref>
<ref id="pone.0185053.ref013"><label>13</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Thol</surname> <given-names>F</given-names></name>, <name name-style="western"><surname>Kade</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Schlarmann</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Loffeld</surname> <given-names>P</given-names></name>, <name name-style="western"><surname>Morgan</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Krauter</surname> <given-names>J</given-names></name>, <etal>et al</etal>. <article-title>Frequency and prognostic impact of mutations in SRSF2, U2AF1, and ZRSR2 in patients with myelodysplastic syndromes</article-title>. <source>Blood</source>. <year>2012</year>; <volume>119</volume>: <fpage>3578</fpage>–<lpage>3584</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1182/blood-2011-12-399337" xlink:type="simple">10.1182/blood-2011-12-399337</ext-link></comment> <object-id pub-id-type="pmid">22389253</object-id></mixed-citation></ref>
<ref id="pone.0185053.ref014"><label>14</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Kang</surname> <given-names>MG</given-names></name>, <name name-style="western"><surname>Kim</surname> <given-names>HR</given-names></name>, <name name-style="western"><surname>Seo</surname> <given-names>BY</given-names></name>, <name name-style="western"><surname>Lee</surname> <given-names>JH</given-names></name>, <name name-style="western"><surname>Choi</surname> <given-names>SY</given-names></name>, <name name-style="western"><surname>Kim</surname> <given-names>SH</given-names></name>, <etal>et al</etal>. <article-title>The prognostic impact of mutations in spliceosomal genes for myelodysplastic syndrome patients without ring sideroblasts</article-title>. <source>BMC Cancer</source>. <year>2015</year>; <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1186/s12885-015-1493-5" xlink:type="simple">10.1186/s12885-015-1493-5</ext-link></comment> <object-id pub-id-type="pmid">26115659</object-id></mixed-citation></ref>
<ref id="pone.0185053.ref015"><label>15</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Wu</surname> <given-names>SJ</given-names></name>, <name name-style="western"><surname>Kuo</surname> <given-names>YY</given-names></name>, <name name-style="western"><surname>Hou</surname> <given-names>HA</given-names></name>, <name name-style="western"><surname>Li</surname> <given-names>LY</given-names></name>, <name name-style="western"><surname>Tseng</surname> <given-names>MH</given-names></name>, <name name-style="western"><surname>Huang</surname> <given-names>CF</given-names></name>, <etal>et al</etal>. <article-title>The clinical implication of SRSF2 mutation in patients with myelodysplastic syndrome and its stability during disease evolution</article-title>. <source>Blood</source>. <year>2012</year>; <volume>120</volume>: <fpage>3106</fpage>–<lpage>3111</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1182/blood-2012-02-412296" xlink:type="simple">10.1182/blood-2012-02-412296</ext-link></comment> <object-id pub-id-type="pmid">22932795</object-id></mixed-citation></ref>
<ref id="pone.0185053.ref016"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Wells GA, Shea B, O'Connell D, Peterson J, Welch V, Losos M, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Available from: <ext-link ext-link-type="uri" xlink:href="http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp" xlink:type="simple">http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp</ext-link></mixed-citation></ref>
<ref id="pone.0185053.ref017"><label>17</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Higgins</surname> <given-names>JP</given-names></name>, <name name-style="western"><surname>Thompson</surname> <given-names>SG</given-names></name>, <name name-style="western"><surname>Deeks</surname> <given-names>JJ</given-names></name>, <name name-style="western"><surname>Altman</surname> <given-names>DG</given-names></name>. <article-title>Measuring inconsistency in meta-analyses</article-title>. <source>BMJ</source>. <year>2003</year>; <volume>327</volume>: <fpage>557</fpage>–<lpage>560</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1136/bmj.327.7414.557" xlink:type="simple">10.1136/bmj.327.7414.557</ext-link></comment> <object-id pub-id-type="pmid">12958120</object-id></mixed-citation></ref>
<ref id="pone.0185053.ref018"><label>18</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Begg</surname> <given-names>CB</given-names></name>, <name name-style="western"><surname>Mazumdar</surname> <given-names>M</given-names></name>. <article-title>Operating characteristics of a rank correlation test for publication bias</article-title>. <source>Biometrics</source>. <year>1994</year>; <volume>50</volume>: <fpage>1088</fpage>–<lpage>1101</lpage>. <object-id pub-id-type="pmid">7786990</object-id></mixed-citation></ref>
<ref id="pone.0185053.ref019"><label>19</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Egger</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Davey</surname> <given-names>SG</given-names></name>, <name name-style="western"><surname>Schneider</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Minder</surname> <given-names>C</given-names></name>. <article-title>Bias in meta-analysis detected by a simple, graphical test</article-title>. <source>BMJ</source>. <year>1997</year>; <volume>315</volume>: <fpage>629</fpage>–<lpage>634</lpage>. <object-id pub-id-type="pmid">9310563</object-id></mixed-citation></ref>
<ref id="pone.0185053.ref020"><label>20</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Wu</surname> <given-names>L</given-names></name>, <name name-style="western"><surname>Song</surname> <given-names>L</given-names></name>, <name name-style="western"><surname>Xu</surname> <given-names>L</given-names></name>, <name name-style="western"><surname>Chang</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Xu</surname> <given-names>F</given-names></name>, <name name-style="western"><surname>Wu</surname> <given-names>D</given-names></name>, <etal>et al</etal>. <article-title>Genetic landscape of recurrent ASXL1, U2AF1, SF3B1, SRSF2, and EZH2 mutations in 304 Chinese patients with myelodysplastic syndromes</article-title>. <source>Tumor Biol</source>. <year>2016</year>; <volume>37</volume>: <fpage>4633</fpage>–<lpage>4640</lpage>.</mixed-citation></ref>
<ref id="pone.0185053.ref021"><label>21</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Cui</surname> <given-names>Y</given-names></name>, <name name-style="western"><surname>Tong</surname> <given-names>H</given-names></name>, <name name-style="western"><surname>Du</surname> <given-names>X.</given-names></name>, <name name-style="western"><surname>Li</surname> <given-names>B</given-names></name>, <name name-style="western"><surname>Gale</surname> <given-names>RP</given-names></name>, <name name-style="western"><surname>Qin</surname> <given-names>T</given-names></name>, <etal>et al</etal>. <article-title>Impact of TET2, SRSF2, ASXL1 and SETBP1 mutations on survival of patients with chronic myelomonocytic leukemia</article-title>. <source>Exp Hematol Oncol</source>. <year>2015</year>; <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1186/s40164-015-0009-y" xlink:type="simple">10.1186/s40164-015-0009-y</ext-link></comment> <object-id pub-id-type="pmid">26019984</object-id></mixed-citation></ref>
<ref id="pone.0185053.ref022"><label>22</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Kim</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Yahng</surname> <given-names>SA</given-names></name>, <name name-style="western"><surname>Kwon</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Park</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Jeon</surname> <given-names>YW</given-names></name>, <name name-style="western"><surname>Yoon</surname> <given-names>JH</given-names></name>, <etal>et al</etal>. <article-title>Mutation in TET2 or TP53 predicts poor survival in patients with myelodysplastic syndrome receiving hypomethylating treatment or stem cell transplantation</article-title>. <source>Bone Marrow Transplant</source>. <year>2015</year>; <volume>50</volume>: <fpage>1132</fpage>–<lpage>1134</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1038/bmt.2015.110" xlink:type="simple">10.1038/bmt.2015.110</ext-link></comment> <object-id pub-id-type="pmid">25961778</object-id></mixed-citation></ref>
<ref id="pone.0185053.ref023"><label>23</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Karimi</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Nilsson</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Dimitriou</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Jansson</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Matsson</surname> <given-names>H</given-names></name>, <name name-style="western"><surname>Unneberg</surname> <given-names>P</given-names></name>, <etal>et al</etal>. <article-title>High-throughput mutational screening adds clinically important information in myelodysplastic syndromes and secondary or therapy-related acute myeloid leukemia</article-title>. <source>Haematologica</source>. <year>2015</year>; <volume>100</volume>: <fpage>e223</fpage>–<lpage>e225</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3324/haematol.2014.118034" xlink:type="simple">10.3324/haematol.2014.118034</ext-link></comment> <object-id pub-id-type="pmid">25769547</object-id></mixed-citation></ref>
<ref id="pone.0185053.ref024"><label>24</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Itzykson</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Kosmider</surname> <given-names>O</given-names></name>, <name name-style="western"><surname>Renneville</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Gelsi-Boyer</surname> <given-names>V</given-names></name>, <name name-style="western"><surname>Meggendorfer</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Morabito</surname> <given-names>M</given-names></name>, <etal>et al</etal>. <article-title>Prognostic score including gene mutations in chronic myelomonocytic leukemia</article-title>. <source>J Clin Oncol</source>. <year>2013</year>; <volume>31</volume>: <fpage>2428</fpage>–<lpage>2436</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1200/JCO.2012.47.3314" xlink:type="simple">10.1200/JCO.2012.47.3314</ext-link></comment> <object-id pub-id-type="pmid">23690417</object-id></mixed-citation></ref>
<ref id="pone.0185053.ref025"><label>25</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Bejar</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Stevenson</surname> <given-names>KE</given-names></name>, <name name-style="western"><surname>Caughey</surname> <given-names>BA</given-names></name>, <name name-style="western"><surname>Abdel-Wahab</surname> <given-names>O</given-names></name>, <name name-style="western"><surname>Steensma</surname> <given-names>DP</given-names></name>, <name name-style="western"><surname>Galili</surname> <given-names>N</given-names></name>, <etal>et al</etal>. <article-title>Validation of a prognostic model and the impact of mutations in patients with lower-risk myelodysplastic syndromes</article-title>. <source>J Clin Oncol</source>. <year>2012</year>; <volume>30</volume>: <fpage>3376</fpage>–<lpage>3382</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1200/JCO.2011.40.7379" xlink:type="simple">10.1200/JCO.2011.40.7379</ext-link></comment> <object-id pub-id-type="pmid">22869879</object-id></mixed-citation></ref>
<ref id="pone.0185053.ref026"><label>26</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Mian</surname> <given-names>SA</given-names></name>, <name name-style="western"><surname>Smith</surname> <given-names>AE</given-names></name>, <name name-style="western"><surname>Kulasekararaj</surname> <given-names>AG</given-names></name>, <name name-style="western"><surname>Kizilors</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Mohamedali</surname> <given-names>AM</given-names></name>, <name name-style="western"><surname>Lea</surname> <given-names>NC</given-names></name>, <etal>et al</etal>. <article-title>Spliceosome mutations exhibit specific associations with epigenetic modifiers and proto-oncogenes mutated in myelodysplastic syndrome</article-title>. <source>Haematologica</source>. <year>2013</year>; <volume>98</volume>: <fpage>1058</fpage>–<lpage>1066</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3324/haematol.2012.075325" xlink:type="simple">10.3324/haematol.2012.075325</ext-link></comment> <object-id pub-id-type="pmid">23300180</object-id></mixed-citation></ref>
<ref id="pone.0185053.ref027"><label>27</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Kim</surname> <given-names>E</given-names></name>, <name name-style="western"><surname>Ilagan</surname> <given-names>JO</given-names></name>, <name name-style="western"><surname>Liang</surname> <given-names>Y</given-names></name>, <name name-style="western"><surname>Daubner</surname> <given-names>GM</given-names></name>, <name name-style="western"><surname>Lee</surname> <given-names>SC</given-names></name>, <name name-style="western"><surname>Ramakrishnan</surname> <given-names>A</given-names></name>, <etal>et al</etal>. <article-title>SRSF2 Mutations Contribute to Myelodysplasia by Mutant-Specific Effects on Exon Recognition</article-title>. <source>Cancer Cell</source>. <year>2015</year>; <volume>27</volume>: <fpage>617</fpage>–<lpage>630</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.ccell.2015.04.006" xlink:type="simple">10.1016/j.ccell.2015.04.006</ext-link></comment> <object-id pub-id-type="pmid">25965569</object-id></mixed-citation></ref>
<ref id="pone.0185053.ref028"><label>28</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Xiao</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Sun</surname> <given-names>Y</given-names></name>, <name name-style="western"><surname>Ding</surname> <given-names>JH</given-names></name>, <name name-style="western"><surname>Lin</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Rose</surname> <given-names>DW</given-names></name>, <name name-style="western"><surname>Rosenfeld</surname> <given-names>MG</given-names></name>, <etal>et al</etal>. <article-title>Splicing regulator SC35 is essential for genomic stability and cell proliferation during mammalian organogenesis</article-title>. <source>Mol Cell Biol</source>. <year>2007</year>; <volume>27</volume>: <fpage>5393</fpage>–<lpage>5402</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1128/MCB.00288-07" xlink:type="simple">10.1128/MCB.00288-07</ext-link></comment> <object-id pub-id-type="pmid">17526736</object-id></mixed-citation></ref>
<ref id="pone.0185053.ref029"><label>29</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Dehm</surname> <given-names>SM</given-names></name>. <article-title>Test-firing ammunition for spliceosome inhibition in cancer</article-title>. <source>Clin Cancer Res</source>. <year>2013</year>; <volume>19</volume>: <fpage>6064</fpage>–<lpage>6066</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1158/1078-0432.CCR-13-2461" xlink:type="simple">10.1158/1078-0432.CCR-13-2461</ext-link></comment> <object-id pub-id-type="pmid">24097858</object-id></mixed-citation></ref>
</ref-list>
</back>
</article>